Nanoscience enables ultrasensitive detection of Alzheimer's biomarker Student: Xu Zhang Christine D. Keating. PNAS 2005, 102, No. 7, 2263 –2264 Jwa-Min.

Slides:



Advertisements
Similar presentations
Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Advertisements

Mechanical and Industrial Engineering University of Massachusetts Amherst, MA, USA Nanomedicine Jonathan P. Rothstein.
Dr. Thaweesak Tirawatnapong Chula Medical Research Center (Chula MRC)
Aptamers in the Real World Development and Applications NeoVentures Biotechnology Inc. Aptamers Applied1.
In the name of God. Summer School Influenza Unit, Pasteur Institute of Iran summer 2012.
Nanomaterial’s Application in Biotechnology Lei Sun Project manager Digital Health Group Intel Corp.
Molecular Biology Lecture 10 Chapter 5 Molecular Tools for Studying Genes and Gene Activity Copyright © The McGraw-Hill Companies, Inc. Permission required.
Cell Separation Using Magnetic Beads
Research Techniques Made Simple: The Use of Luminex Assays To Measure Cytokines Saami Khalifian, B.A., Giorgio Raimondi, Ph.D., & Gerald Brandacher, M.D.
Measurement in Science Bioassays and Immunoassays Karim Meeran 23 October 2009.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
Bio-barcode Amplification meets Nanoarray: High throughput functional genomics and proteomics study in single cell level Student: Xu Zhang If I were a.
Introduction to Immunoassays
Nanotechnology and medicine Dina Khater – 3 April SFC.
Variants of PCR Lecture 4
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
with an emphasis on DNA microarrays
(Enzyme Linked Immunosorbent Assay)
Objective DNA amplification (eg. PCR)    advances in forensic, clinical applications Comparable protein amplification tools (?)  aid medical diagnostics,
Lec 16 Medical biotechnology Shah Rukh Abbas, PhD
There are currently 26 million people worldwide with Alzheimer’s disease. This figure is projected to grow to more than 106 million people by 2050.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 22 Alzheimer’s Disease.
-The methods section of the course covers chapters 21 and 22, not chapters 20 and 21 -Paper discussion on Tuesday - assignment due at the start of class.
Protein Misfolding: Therapeutic Implications
Western Blotting.
WHAT IS A WESTERN BLOT?.
A carboxylated Zn-phthalocyanine inhibits the fibril formation of Alzheimer’s amyloid β peptide Atsushi Nagai Dept. Laboratory Medicine Shimane University.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
A New Oklahoma Bioinformatics Company. Microarray and Bioinformatics.
HIV variants and US licensed assays Indira Hewlett, Ph.D Chief, Lab. of Molecular Virology CBER/FDA XIX SOGAT, 2006.
Alzheimer’s Disease. Alzheimer's is a the most common form of dementia. Nearly 50-80% of all dementia patients have Alzheimer's. It is a progressive fatal.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
MLAB 2401: Clinical Chemistry Keri Brophy-Martinez Immunoassays 1.
NON-UNION FRACTURE REFERRAL CHAIN Fracture X-ray image Cast Cast removed One more follow up visit in 2 months if needed 3-6 (typical) weeks 24 hours or.
E-beam Size-Dependent Self- Assembly Protein Array.
Top-Down Meets Bottom-Up: Dip-Pen Nanolithography and DNA-Directed Assembly of Nanoscale Electrical Circuits Student: Xu Zhang Chad A. Mirkin et al. Small.
Nanotechnology The concept of nanotechnology is defined as an art handling of tiny particles (1nm= m). The structures have different properties.
Lecturer: David. * Reverse transcription PCR * Used to detect RNA levels * RNA is converted to cDNA by reverse transcriptase * Then it is amplified.
ANALYSIS OF GENE EXPRESSION DATA. Gene expression data is a high-throughput data type (like DNA and protein sequences) that requires bioinformatic pattern.
Epidemiology of Alzheimer’s Disease
Western Blotting. Introduction … Western blotting, also known as immunoblotting or protein blotting, is a technique used to detect the presence of a specific.
B Lymphocytes The response of B lymphocytes to a foreign antigen, clonal selection and the release of monoclonal antibodies (the humoral response). Definition.
Alzheimer's disease 蕭尚益 丁唯洋 蔡欣容. Outline introductionDisease mechanismPreventConclusion.
Nanoparticle-Based Bio-Bar Codes
Biomarkers of Alzheimer’s Disease. Objectively mark Presence of neurodegenerative pathology Change in pathologic activity Purpose.
Microarray: An Introduction
NANOTECHNOLOGY IN CANCER TREATMENT
ICC Immunocytochemistry
Applications of Nanotechnology in Alzheimer’s Disease BioE 494 – Atomic and Molecular Nanotechnology Fall 2007 Deivya Bansal.
ELISA BASICS.
MONOCLONAL ANTIBODIES What are they? How are they produced? What potential uses?
CONTENTS INTRODUCTION COMPONENTS OF BIOSENSORS NANOBIOSENSORS TYPES OF NANOSENSORS AND THEIR APPLICATIONS ENVIRONMENTAL APPLICATIONS FUTURE APPLICATION.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
José L Molinuevo, Craig Ritchie, Miia Kivipelto
COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE   Mirjana Babić Leko1, Matea Nikolac Perković2,
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
A non-amplification molecular probe approach John Gerdes, Ph. D.
Image Challenge Q: A 70-year-old woman presented to the neurology clinic with a 2-year history of gait disturbance, cognitive impairment, and urinary incontinence.
SOUTHERN BLOTTING Ali Zaeri Medical Genetics and diagnostic lab Lab 5.
Down-Regulation of miRNAs by Mutated FOXP2
Early Dementia Distinguishing AD From MCI
SCIENCE VOL SEPTEMBER 2003 Nanoparticle-Based Bio–Bar Codes for the Ultrasensitive Detection of Proteins Jwa-Min Nam,* C. Shad Thaxton,* Chad A.
Detection of HIV-1 Minority Variants Containing the K103N Drug-Resistance Mutation Using a Simple Method to Amplify RNA Targets (SMART)  Kenneth Morabito,
Molecular diagnosis of viral hepatitis
José L Molinuevo, Craig Ritchie, Miia Kivipelto
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Transcription Protein Synthesis.
Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.
The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease  Konrad Talbot, Hoau-Yan Wang 
Detecting and Diagnosing Alzheimer’s Disease
Presentation transcript:

Nanoscience enables ultrasensitive detection of Alzheimer's biomarker Student: Xu Zhang Christine D. Keating. PNAS 2005, 102, No. 7, 2263 –2264 Jwa-Min Nam, Shad Thaxton, Chad A. Mirkin. Science 2003, 301,

Alzheimer's disease Alzheimer's disease (AD), which afflicts an estimated 16 million people worldwide, is a neurodegenerative dementia characterized by memory loss and cognitive impairment. Symptoms begin with mild cognitive impairment. It’s tough to distinguish from other more benign forms of age-related dementia.

Alzheimer's disease Smaller, soluble oligomers of peptides, referred to as amyloid--derived diffusible ligands (ADDLs), have recently been hypothesized as the causative agent in AD- related memory loss. Support for the role of ADDLs comes from their neurotoxicity, and mouse studies that indicate a reversal of memory loss upon injection of amyloid- antibodies This paper presented an ultrasensitive, nanoparticle-based protein detection strategy termed bio-barcode amplification (BCA) to detect ADDL concentration in the cerebrospinal fluid (CSF).

Bio-barcode Amplification (BCA) Strategy CSF is first exposed to monoclonal anti-ADDL antibodies bound to magnetic microparticles. After ADDL binding, the microparticles are separated with a magnetic field and washed before addition of secondary antibodies bound to DNA:Au nanoparticle conjugates. Unreacted Au nanoparticle conjugates are removed after magnetic separation, then elevated temperature release the barcode DNA for analysis. Each Au nanosphere carries hundreds of identical barcode DNA strands, providing substantial amplification.

Scanometric DNA detection The probe strands are arrayed on a solid support and the detection strand is bound to an Au nanosphere. The selectively assembled Au nanospheres then act as nucleation sites for Ag deposition upon the chemical reduction of Ag+ from solution. The resulting Ag deposits can be quantified by a simple desktop scanner such as is used to scan documents for computer manipulation (hence scanometric)

Advantages Ultrasentivity with built-in signal amplification mechanism. 30 attomolar (30 x M) for protein targets, useful for early diagnosis. Can also be applicable for DNA or RNA diagnosis, or simultaneously multiple monitoring. Rapid diagnosis due to performing the BCA assay in homogeneous suspension. It marks one of the first real applications of nanotechnology, while the vast majority of the countless publications on nanoparticle-based diagnostics are in the proof-of-principle stage.